Monte Rosa Therapeutics, Inc. GLUE CCNE One — External Research And Development Expense

Similar metrics at other companies

RAPPPreclinical Programs External Expenses — Research And Development Expense

$4.29M+32.1%

ABSIExternal preclinical and clinical development — R&D

$4.29M+59.7%

IDYAIDE397 — External Clinical Development Expenses

$3.52M-6.0%

INVAExternal Services — Research And Development Expense

$2.61M-14.6%

BCRXBCX17725 — Research and Development Expense (Excluding Acquired in Process Cost)

$1.91M-22.4%

IDYAIDE849 — External Clinical Development Expenses

$4.77M+1,026%

Questions, answered.

What is Monte Rosa Therapeutics, Inc.'s CCNE one — external research and development expense?

Monte Rosa Therapeutics, Inc. (GLUE) reported CCNE one — external research and development expense of $1.7M in Q1 2026.

What does CCNE one — external research and development expense mean?

This metric represents the total costs incurred for outsourced research and development activities specifically associated with the CCNE One program. It captures payments to contract research organizations, external laboratories, and third-party collaborators essential for advancing this specific therapeutic candidate through preclinical or clinical development stages. Tracking this expense provides insight into the capital intensity and external resource dependency required to progress this particular asset within the company's pipeline.